Biomarker validation: In situ analysis of protein expression using semiquantitative immunohistochemistry-based techniques

Clinical Colorectal Cancer

Volumn 7, Issue 3, 2008, Pages 172-177

  Sullivan, Catherine A W ^a   Chung, Gina G ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Chromagen; Formalin fixation; Recipient block; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FORMALDEHYDE; RNA;

CANCER DIAGNOSIS; COLORECTAL CANCER; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LASER CAPTURE MICRODISSECTION; NORTHERN BLOTTING; PANCREAS CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOFT TISSUE SARCOMA; TISSUE MICROARRAY; VALIDATION PROCESS;

GENE EXPRESSION PROFILING; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEOMICS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 44449153887     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.022     Document Type: Review

References (39)

1. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286:531-7.
2. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000; 1:48-56.
3. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-74.
4. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7:545-53.
5. Chuaqui RF, Bonner RF, Best CJ, et al. Post-analysis follow-up and validation of microarray experiments. Nat Genet 2002; 32(suppl):509-14.
6. Taniguchi M, Miura K, Iwao H, et al. Quantitative assessment of DNA microarrays - comparison with Northern blot analyses. Genomics 2001; 71:34-9.
7. Rajeevan MS, Vernon SD, Taysavang N, et al. Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR. J Mol Diagn 2001; 3:26-31.
8. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006; 4(suppl 3):S1-22.
9. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357:1496-506.
10. Espina V, Mehta AI, Winters ME, et al. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003; 3:2091-100.
11. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20:1981-9.
12. van de Rijn M, Gilks CB. Applications of microarrays to histopathology. Histopathology 2004; 44:97-108.
13. Giltnane JM, Rimm DL. Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 2004; 1:104-11.
14. Taylor CR, Levenson RM. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology 2006; 49:411-24.
15. Watanabe A, Cornelison R, Hostetter G. Tissue microarrays: applications in genomic research. Expert Rev Mol Diagn 2005; 5:171-81.
16. Werner M, Chott A, Fabiano A, et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000; 24:1016-9.
17. Mandell JW. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 2003; 163:1687-98.
18. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80:1943-9.
19. Shi SR, Liu C, Taylor CR. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J Histochem Cytochem 2007; 55:105-9.
20. Pozner-Moulis S, Cregger M, Camp RL, et al. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest 2007; 87:251-60.
21. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 1986; 55:244-8.
22. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-7.
23. DiVito KA, Charette LA, Rimm DL, et al. Long-term preservation of antigenicity on tissue microarrays. Lab Invest 2004; 84:1071-8.
24. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159:2249-56.
25. García JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003; 101:681-9.
26. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003; 16:902-12.
27. Engellau J, Akerman M, Anderson H, et al. Tissue microarray technique in soft tissue sarcoma: immunohistochemical Ki-67 expression in malignant fibrous histiocytoma. Appl Immunohistochem Mol Morphol 2001; 9:358-63.
28. Jourdan F, Sebbagh N, Comperat E, et al. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 2003; 443:115-21.
29. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19:3808-16.
30. Chung GG, Kielhorn EP, Rimm DL. Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray. Clin Colorectal Cancer 2002; 1:237-42.
31. Sirota RL. Error and error reduction in pathology. Arch Pathol Lab Med 2005; 129:1228-33.
32. Rubin MA, Zerkowski MP, Camp RL, et al. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2004; 164:831-40.
33. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8:1323-7.
34. Camp RL, Dolled-Filhart M, King BL, et al. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003; 63:1445-8.
35. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11:5856-62.
36. Zerkowski MP, Camp RL, Burtness BA, et al. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest 2007; 25:19-26.
37. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005; 97:1808-15.
38. Mertz KD, Demichelis F, Kim R, et al. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol 2007; 38:1454-62.
39. Berger AJ, Kluger HM, Li N, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003; 63:8103-7.